<DOC>
	<DOCNO>NCT00258700</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority candidate Hib-MenC conjugate vaccine co-administered Infanrix™-IPV versus license meningococcal serogroup C vaccine co-administered Pediacel™ give accord 2 , 3 , 4 month schedule immunogenicity Hib-MenC vaccine give booster dose 12-15 month age .</brief_summary>
	<brief_title>Primary &amp; Booster Immunogenicity Study GSK Biologicals ' Hib-MenC Versus Licensed Men-C Vaccine</brief_title>
	<detailed_description>This multicenter study open respect treatment allocation , double-blind respect Hib-MenC-TT lot ( 3 lot ) . The study conduct two stage . Primary vaccination phase : 3 dos Hib-MenC-TT Infanrix™-IPV control group license Men-C vaccine Pediacel™ 2 , 3 , 4 month age ; Booster/persistence phase : 1 dose Hib-MenC Priorix™ . 4 blood sample 3.5ml ( 5ml UK subset ) collect ( Study Months 0 &amp; 3 , prior &amp; 42 day booster ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy male female , , include , 6 12 week age . Born gestation period 36 42 week Vaccination hepatitis B birth 6 12 week ( concomitantly first study vaccine ) , accept although mandatory Exclusion criterion : Planned administration/ administration vaccine foreseen study protocol since birth , exception Bacille Calmette Guerin ( BCG ) hepatitis B vaccine . History H. influenzae type b /or meningococcal serogroup C disease . Previous vaccination meningococcal serogroup C disease , diphtheria , tetanus , pertussis , polio Hib disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection A family history congenital hereditary immunodeficiency History neurologic disorder seizures History allergic disease reaction likely exacerbate component vaccine</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>